Compare Summit Therapeutics Inc (SMMT) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Summit Therapeutics Inc trades at $17.36 (market cap $13.71B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.72 (market cap $3.14B). The key difference: Summit Therapeutics Inc is far larger — about 4.4× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 1,461,349). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| SMMT | SPHD | |
|---|---|---|
Market Cap | $13.71B | $3.14B |
Volume | 6,173,057 | 1,461,349 |
Sector | Health | — |
52-Week High | $26.38 | $53.55 |
52-Week Low | $12.43 | $46.96 |
Typical Hold Time | 16 Days | 125 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
SPHD trades at $48.72 with a 1.1% daily gain, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Key support sits at $47 with resistance at $49.
The outlook remains cautious given bearish technical signals and competitive pressure from higher-performing dividend ETFs. While monthly dividends appeal to income-focused investors, SPHD's lack of quality screening exposes it to yield traps. Near-term performance depends on market volatility and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
